Navigation Links
Consumer Groups Will Continue to Press Stem Cell Patent Challenge
Date:2/28/2008

SANTA MONICA, Calif., Feb. 28 /PRNewswire-USNewswire/ -- Two consumer groups said today that they will continue their challenge of three overreaching patents on human stem cells held by the Wisconsin Alumni Research Foundation (WARF) despite a non-final decision by Patent Office allowing three amended claims in one of the disputed patents.

The Foundation For Taxpayer and Consumer Rights (FTCR) and the Public Patent Foundation (PUBPAT) said they would appeal any later final decision by the examiner supporting the claims to the Patent and Trademark Office's Board of Appeals, which frequently overturns the decision made by examiners. The groups also have the right to appeal any decision of that board to the U.S. Circuit Court for the Federal Circuit, if necessary.

The "non-final office decision" in the inter partes re-examination of the '913 patent was posted late Wednesday on the PTO's website.

"We won the first round when the PTO rejected all claims of the '780, '806 and '913 patents," said John M. Simpson, FTCR Stem Cell Project Director. "Now WARF has won the second round with respect to just one of the patents, but the battle is hardly over. We're in this for the long haul."

"The examiner based his decision on his own belief that it would not have been obvious to isolate human stem cells using widely known methods to isolate mouse stem cells, which contradicts the sworn testimony that we provided of four renowned stem cell embryologists who were doing such work", said Dan Ravicher, PUBPAT Executive Director. "Thus, the examiner took his own opinion over the opinions of our four leading stem cell scientist witnesses."

Joining the two consumer groups in the challenge from the beginning was Dr. Jeanne Loring, now of the Scripps Institute. After the initial rejection, Dr. Alan Trounson, then of Australia's Monash University and now president of the California Institute for Regenerative Medicine, Dr. Douglas Melton of Harvard and Dr. Chad Cowan of Harvard filed affidavits supporting the challenge.

The two groups noted that the patent challenge has already improved the situation for stem cell researchers; shortly after the PTO announced it would re-examine the three patents, WARF announced a substantial easing of its licensing requirements.

"WARF executives were acting like arrogant bullies blinded by dollar signs," said Simpson. "Our challenge has engendered a more co-operative stance on their part."

Decisions are pending on the other two patents. No other country recognizes the three WARF patents.

The Foundation for Taxpayer and Consumer Rights is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at: http://www.ConsumerWatchdog.org.

The Public Patent Foundation is a not-for-profit legal services organization that represents the public's interests against the harms caused by the patent system, particularly the harms caused by wrongly issued patents and unsound patent policy. For more information, visit us on the web at http://www.pubpat.org.


'/>"/>
SOURCE Foundation for Taxpayer and Consumer Rights
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eyes on Puerto Rico: Johnson & Johnson Markets New Contact Lenses Directly to Consumers
2. Health and Fashion - Dow Corning Predicts the Top Trends Driving Consumers to the Beauty Counters
3. Weight Watchers to Present at Bank of America 2008 Consumer Conference
4. Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS 08
5. Microsoft to Showcase Innovative Solutions for Healthcare Providers and Consumers at HIMSS 2008 Annual Conference & Exhibition
6. Consumer Group Welcomes Introduction of Stem Cell Agency Oversight Bill
7. Men Are Vein Too: Innovative Treatment Sparks Unexpected Consumer Trend
8. Clarity for Consumers on Botox Complication and Death Reports
9. IHF Says Google Personal Health-Records System Gives Consumers Greater Control Over Privacy than HIPAA Rules
10. Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery
11. Wyeth Consumer Healthcare Names New Head of Global R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology: